Dissertation
Dissertation > Medicine, health > Chinese Medicine > Of Pharmacy > Pharmacology > Chinese medicine Experimental Pharmacology

Effect of the Small Dose Triptolide on Tumor Growth and Immune Function of Ovarian Cancer Rat

Author ZouDangHua
Tutor TanBuZhen
School Nanchang University
Course Obstetrics and Gynaecology
Keywords Triptolide Ovarian cancer in rats Splenic lymphocyte transformation rate TNF-a IL-2
CLC R285.5
Type Master's thesis
Year 2009
Downloads 68
Quotes 0
Download Dissertation

Objective: To establish an animal model of ovarian cancer, given the different small dose triptolide, Dutch ovarian cancer rat tumor growth and immune function changes observed after treatment. Small doses of triptolide on tumor growth in rats bearing ovarian cancer and immune function, Triptolide provide experimental evidence for the treatment of patients with ovarian cancer. Methods: In vitro cultured the inbred Fischer344 rats poorly differentiated epithelial ovarian cancer cell line NUTU-19. 48 Fischet344 rat, eight randomly selected for the normal group, the remaining 40 rats, the cancer cells to 2 × 106 / The number of tumor cell suspension were inoculated rats with right axillary subcutaneous rat model of ovarian cancer subcutaneous metastases. When the the rat right axillary tumor grew to about 0.4 × 0.4cm2 size, tumor-bearing rats were randomly divided into five groups; blank tumor-bearing groups: per intraperitoneal injection of saline 2 ml of; cisplatin group: each 3mg/kg. d the cisplatin with saline 2ml preparation intraperitoneal injection; the triptolide A group: the each 0.1mg/kg.d triptolide preparation with saline 2ml intraperitoneal injection; triptolide group B: each 0.05 mg / kg.d triptolide formulated with saline 2ml intraperitoneal injection; triptolide group C: each 0.025mg/kg.d paired with saline 2ml intraperitoneal injection; each group the next day injection time, continuous medication 5 times. 24 hours after the last dose, the rats in each group were sacrificed. Weighing method inhibitory rate was calculated; each rat spleen lymphocyte transformation rate by MTT assay and ELISA assay each rat serum TNF-a and IL-2 levels. Results: 1. Triptolide on tumor growth in rats: Triptolide alcohol group A, group B, group C the ovarian tumor inhibition rate were 39.13%, 31.10%, 22.76%, cisplatin group tumor inhibition rate 42.13% of Triptolide A group, the cisplatin group and blank tumor group difference was statistically significant (P lt; 0.05), triptolide group B, C group and blank tumor group difference was not statistically significance (P gt; 0.05), the triptolide A group cisplatin group difference was not statistically significant (P gt; 0.05). Triptolide immune function in rats: (1) Triptolide alcohol group A, B group, C group and cisplatin group rat spleen lymphocyte transformation rate were 1.165 ± 0.04,1.181 ± 0.06 , 1.208 ± 0.07,1.157 ± 0.04, were lower than the blank tumor group (1.254 ± 0.05), the differences were statistically significant (P lt; 0.05), triptolide groups compared with cisplatin group, no statistical difference significance (P gt; 0.05). (2) triptolide group A, group B, group C and cisplatin serum IL-2 value were 70.38 ± 6.89ρg/ml, the the 85.73 ± 8.38ρg/ml 92.06 ± 10.01ρg/ml, 74.49 the ± 11.96ρg/ml, were lower than the blank tumor group (108.94 ± 18.90ρg/ml), and the differences were statistically significant (P lt; 0.05), triptolide group A, group B with cisplatin group difference was not statistically significant (P gt; 0.05), triptolide Group C and cisplatin group difference was statistically significant (P lt; 0.05). (3) Triptolide alcohol A group and B group, C group and cisplatin group, serum TNF-a value is 147.29 ± 29.33ρg/ml, the 187.09 ± 30.67ρg/ml, 198.64 in ± 28.37ρg/ml, 118.98 ± 25.48ρg/ml, are lower than the tumor group (228.84 ± 32.56ρg/ml), the differences were statistically significant (P lt; 0.05), triptolide Group A with cisplatin group difference was not statistically significance (P gt; 0.05), Triptolide alcohol group B, group C and cisplatin group difference was statistically significant (P lt; 0.05). Conclusion: (1) Triptolide Dutch ovarian cancer subcutaneous tumor growth inhibition, the triptolide minimum effective dose is 0.1mg/kg with cisplatin antitumor effect, the results of this study show that quite Triptolide expected for the treatment of cisplatin-resistant ovarian cancer patients. (2) small doses of triptolide inhibition of tumor-bearing rats immune function, can inhibit the Dutch ovarian cancer rat spleen lymphocyte proliferation and lower bearing ovarian cancer serum IL-2, TNF-a levels , but its inhibitory effect on immune function with cisplatin role no significant difference further triptolide treatment of cisplatin-resistant ovarian cancer patients become possible. (3) In this study, rats bearing ovarian cancer animal model, Triptolide significantly inhibited ovarian cancer, although inhibition of immune function in rats, but its inhibitory effect on immune function and cisplatin the role of significant differences, to provide the basis of animal experiments Triptolide treatment of cisplatin-resistant ovarian cancer patients.

Related Dissertations
More Dissertations